← Alaunos Therapeutics, Inc. (TCRT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Alaunos Therapeutics, Inc. (TCRT)
Pharmaceutical Preparations · market cap $9M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
9
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Alaunos Therapeutics (TCRT) is a micro-cap pharmaceutical company with a $50M market cap, 1 reported employee, and approximately $0.4M in cash — implying a runway of roughly one month. The company carries a pipeline including a Phase 3 asset (doxorubicin in combination with palifosfamide-tris for soft tissue sarcoma) alongside several Phase 2 programs, but its financial position is acutely precarious.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Palifosfamide Tris and Doxorubicin | Phase 2 | Soft Tissue Sarcoma |
| Darinaparson | Phase 2 | Multiple Myeloma |
| Indibulin | Phase 2 | Metastatic Breast Cancer |
| Darinaparsin | Phase 2 | Hematologic Neoplasms |
| ZIO-201 | Phase 2 | Advanced Sarcoma |
| doxorubicin in combination with palifosfamide-tris | Phase 3 | Soft Tissue Sarcoma |
| INXN-2001 | Phase 2 | Melanoma |
| ZIO-101 (Darinaparsin) | Phase 2 | Multiple Myeloma |
| INXN-1001 | Phase 2 | Melanoma |
Price & technical context
3-month
-7.5%
6-month
-31.1%
12-month
-27.0%
52-wk range
$0.74–$4.36
vs 50-day MA
+12.1%
vs 200-day MA
-20.3%
Realized vol
148.1%
Max drawdown
-85.6%
Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TCRT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.